{
  "_metadata": {
    "version": "2.0",
    "ticker": "NUVL",
    "asset_id": "nvl330",
    "internal_id": "NVL-330",
    "data_source": "Nuvalent Overview January 12, 2026; Sun Y. et al AACR 2024, AACR-NCI-EORTC 2025",
    "extraction_date": "2026-02-04",
    "last_updated": "2026-02-04"
  },
  "asset": {
    "name": "NVL-330",
    "internal_id": "NVL-330",
    "modality": "Small molecule tyrosine kinase inhibitor",
    "route": "Oral",
    "dose": "TBD (dose escalation ongoing)",
    "formulation": "Oral"
  },
  "target": {
    "primary_target": "HER2 (ERBB2)",
    "target_class": "Receptor tyrosine kinase",
    "biology": {
      "function": "HER2 is a receptor tyrosine kinase that when mutated (especially exon 20 insertions), amplified, or overexpressed drives tumor growth through oncogenic signaling",
      "prevalence": {
        "her2_mutant": "~2-4% of NSCLC",
        "her2_amplified": "~1-5% of NSCLC"
      },
      "cns_involvement": {
        "at_diagnosis": "~19% present with CNS disease",
        "at_1L_progression": "~50% have CNS disease"
      },
      "mutation_types": {
        "exon_20_insertions": "Most common (e.g., YVMA insertion, GSP insertion)",
        "point_mutations": ["S310F", "R678Q", "L755S", "G776V", "V777L", "V777M", "V842I"],
        "amplification": "Wild-type HER2 gene copy number increase"
      }
    },
    "genetic_validation": {
      "oncogenic_driver": "Yes - HER2 mutations and amplifications are validated oncogenic drivers in NSCLC",
      "predictive_biomarker": "HER2 mutation status by NGS; HER2 amplification by FISH/IHC",
      "therapeutic_precedent": "T-DXd (ADC, accelerated approval); Zongertinib (TKI, accelerated approval); Multiple investigational HER2 TKIs"
    },
    "why_good_target": {
      "rationale": [
        "Validated oncogenic driver with emerging therapeutic options",
        "Current TKIs have EGFR-related toxicities (skin rash, diarrhea) or suboptimal CNS activity",
        "ADC (T-DXd) has chemotherapy-like safety profile (30% serious adverse reactions)",
        "High rate of CNS progression warrants brain-penetrant therapies"
      ],
      "unmet_need": [
        "No approved HER2 TKI with both strong CNS activity AND EGFR-sparing profile",
        "Treatment-limiting adverse events with pan-ERBB inhibitors",
        "Suboptimal CNS activity with some approved/investigational agents",
        "No clear 3L+ standard of care"
      ]
    }
  },
  "mechanism": {
    "mechanism_of_action": "HER2-selective, EGFR-sparing tyrosine kinase inhibitor",
    "binding_mode": "ATP-competitive kinase inhibitor designed to selectively inhibit HER2 while sparing EGFR",
    "selectivity_profile": {
      "her2_vs_egfr": "High selectivity for HER2 and HER2 mutants over wild-type EGFR",
      "comparison_to_competitors": {
        "vs_poziotinib": "Greater selectivity for HER2ex20 over EGFR than pan-ERBB inhibitors",
        "vs_zongertinib": "Similar HER2 activity with potentially improved brain penetration"
      }
    },
    "in_vitro_activity": {
      "her2_wild_type_amp": "Potent activity in NCI-H2170, BT-474, NCI-N87 (HER2amp) cell lines",
      "her2_ex20ins": "Potent activity against HER2YVMA, HER2VC, HER2GSP insertions",
      "her2_point_mutations": "Activity against S310F, R678Q, L755S, G776V, V777L, V777M, V842I"
    },
    "brain_penetration": {
      "kp_uu": "~0.15 (rats) - superior to zongertinib",
      "comparison": "Similar to preclinical observations for lorlatinib",
      "preclinical_intracranial_efficacy": {
        "model": "NCI-N87 intracranial tumor model",
        "observation": "NVL-330 induced intracranial tumor regression in mice progressing on zongertinib",
        "zongertinib_exposure": "30 mg/kg BID (estimated above approved human doses of 120-180 mg QD)",
        "crossover_response": "84% tumor reduction with NVL-330 after 124% increase on zongertinib"
      }
    }
  },
  "clinical_data": {
    "trial_name": "HEROEX-1",
    "clinicaltrials_gov": "NCT06521554",
    "trial_design": {
      "phase": "Phase 1a/1b",
      "design": "First-in-human, BOIN dose-escalation with dose expansion",
      "phase_1a": {
        "design": "BOIN dose-escalation",
        "population": "HER2 mutation or HER2 amplification allowed",
        "dose_levels": "DL1 through DL7+"
      },
      "phase_1b": {
        "design": "Dose expansion at candidate RP2Ds",
        "population": "HER2 mutation only"
      }
    },
    "enrollment": {
      "target": "Up to ~120 patients",
      "status": "Enrollment ongoing"
    },
    "key_eligibility": {
      "prior_therapy": "â‰¥1 prior systemic therapy including platinum-based chemotherapy +/- immunotherapy",
      "prior_her2_tkis": "Excluded (prior selective HER2 TKI; note: prior HER2 antibodies and ADCs allowed)",
      "exclusions": "Concurrent oncogenic drivers (EGFR, BRAF, MET, ROS1, ALK, RET)"
    },
    "objectives": {
      "phase_1a": ["Safety/tolerability", "Select candidate RP2D(s)"],
      "phase_1b": ["Safety/tolerability", "Confirm RP2D"]
    },
    "status": "Early-stage enrollment; no efficacy data disclosed yet"
  },
  "competitive_landscape": {
    "approved_therapies": {
      "t_dxd_enhertu": {
        "type": "ADC (HER2-directed antibody-drug conjugate)",
        "approval": "Accelerated approval for HER2-mutant NSCLC",
        "efficacy": "58% ORR, 8.7 month mDOR",
        "limitations": [
          "Chemotherapy-like safety profile",
          "30% serious adverse reactions",
          "Not orally administered"
        ]
      },
      "zongertinib_hernexeos": {
        "type": "Oral HER2 TKI",
        "approval": "Accelerated approval (FDA 2025)",
        "strengths": ["Oral small molecule", "HER2 activity", "HER2ex20 activity"],
        "limitations": ["May have suboptimal CNS activity based on preclinical comparisons"]
      }
    },
    "investigational_therapies": {
      "other_her2ex20_tkis": {
        "examples": ["Pyrotinib", "ORIC-114", "Sevabertinib"],
        "general_limitations": ["Variable EGFR inhibition (skin rash, diarrhea)", "Variable CNS activity"]
      }
    },
    "standard_of_care": {
      "1L": "Pemetrexed + Platinum + Pembrolizumab (48% ORR, 11.2 month mDOR, 8.8 month mPFS)",
      "2L": "T-DXd (accelerated approval)",
      "3L_plus": "No clear standard of care"
    }
  },
  "nvl330_differentiation": {
    "design_goals": [
      "Oral small molecule",
      "HER2 activity including wild-type (amplified) and mutant",
      "HER2ex20 insertion activity",
      "EGFR-sparing to avoid skin rash and diarrhea",
      "CNS activity for brain metastases"
    ],
    "preclinical_advantages": [
      "Broad HER2 activity covering mutations, insertions, and amplification",
      "Greater selectivity for HER2 over EGFR than pan-ERBB inhibitors",
      "Superior brain penetration vs zongertinib in preclinical models",
      "Intracranial activity in zongertinib-progressing model"
    ]
  },
  "investment_analysis": {
    "stage_value": "Early Phase 1 - highest risk, highest upside optionality",
    "differentiation_strength": "Potentially strong if CNS activity and EGFR-sparing confirmed clinically",
    "competitive_position": "Differentiated design vs approved options; clinical proof-of-concept pending",
    "data_quality": "Preclinical only; no clinical efficacy data yet",
    "regulatory_pathway": "Standard IND-to-approval; years from potential approval",
    "commercial_potential": {
      "addressable_market": "HER2-mutant (~2-4%) + HER2-amplified (~1-5%) NSCLC",
      "key_commercial_factors": [
        "CNS activity differentiation vs zongertinib could be significant",
        "EGFR-sparing profile may improve tolerability vs pan-ERBB TKIs",
        "ADC competitor (T-DXd) has different safety/convenience profile"
      ]
    },
    "key_data_to_watch": [
      "Phase 1a dose-escalation safety and PK",
      "Early signs of clinical activity",
      "CNS responses in patients with brain metastases",
      "EGFR-related AE incidence (skin rash, diarrhea)"
    ]
  },
  "catalysts": [
    {
      "event": "HEROEX-1 Phase 1a/1b progress",
      "timing": "Throughout 2026",
      "significance": "Third program advancement; dose optimization"
    },
    {
      "event": "Initial clinical data disclosure (if available)",
      "timing": "TBD (potentially 2026-2027)",
      "significance": "First clinical proof-of-concept"
    }
  ]
}
